Form 4: Xeris Biopharma CMO's RSU Tax Withholding

Xeris Biopharma Holdings, Inc.'s Chief Medical Officer, Anh Tu Nguyen, reported the withholding of 29,300 common shares for tax obligations related to vested restricted stock units.

Summary

• Anh Tu Nguyen, Chief Medical Officer of Xeris Biopharma Holdings, Inc., reported a transaction involving the company's common stock.
• On February 24, 2026, 29,300 shares of common stock were withheld by the issuer.
• This withholding was to satisfy income tax and other obligations related to the net settlement of restricted stock units that vested on the same date.
• The shares were valued at $6.88 per share for the purpose of this transaction.
• Following this transaction, Mr. Nguyen directly beneficially owns 395,023 shares of common stock.
• Additionally, Mr. Nguyen indirectly beneficially owns 3,710 shares via an IRA and 3,501 shares via children's IRAs, disclaiming beneficial ownership except for his pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine administrative transaction related to executive compensation rather than a strategic or operational development.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not typically provide broader industry context. This specific filing details a routine tax withholding event common for executives receiving equity compensation.

Comparison to Industry Standards

• Not applicable. This Form 4 reports a routine insider transaction (tax withholding on RSU vesting) specific to Xeris Biopharma Holdings, Inc. and does not provide data for comparison against industry benchmarks or competitor performance.

Related Party Transactions

• The transaction involves the withholding of shares by the issuer (Xeris Biopharma Holdings, Inc.) from an officer (Anh Tu Nguyen) to cover tax liabilities related to vested restricted stock units, which is a standard compensation-related transaction rather than an unusual related party dealing.

Stakeholder Impact

• Minimal impact on shareholders, as this is a routine administrative transaction related to executive compensation.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Keywords

Xeris Biopharma, XERS, Form 4, insider transaction, restricted stock units, RSU, tax withholding, beneficial ownership, Chief Medical Officer, Anh Tu Nguyen